Breaking News, Collaborations & Alliances

MorphoSys Achieves HuCAL Clinical Milestone

MorphoSys AG will receive a milestone payment from Centocor Ortho Biotech, Inc. for the initiation of a Phase I trial using a HuCAL-derived, fully human antibody in the therapeutic area of inflammation.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MorphoSys AG will receive a milestone payment from Centocor Ortho Biotech, Inc. for the initiation of a Phase I trial using a HuCAL-derived, fully human antibody in the therapeutic area of inflammation. “The advancement of a new HuCAL antibody into human clinical trials is an important step forward for MorphoSys,” commented Dr. Simon Moroney, chief executive officer of MorphoSys. “Progress in the development of innovative biopharmaceutical agents by our partners is a key dri...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters